US45826J1051

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

November 08, 2025 17:13 ET  | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…

6 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025 16:01 ET  | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics,…

1 month ago